منابع مشابه
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and their analogues have been reported to show antiangiogenic activities. Compared with the drugs in the clinic, these agents display interesting characteristics, including diverse sources, unique chemical structures, special modes of action, and distinct activity and toxic...
متن کاملSTAT inhibitors for cancer therapy
Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been deve...
متن کاملSTAT3 inhibitors for cancer therapy
The signal transducer and activator of transcription STAT3 is a transcription factor which plays a key role in normal cell growth and is constitutively activated in about 70% of solid and hematological cancers. Activated STAT3 is phosphorylated on tyrosine and forms a dimer through phosphotyrosine/src homology 2 (SH2) domain interaction. The dimer enters the nucleus via interaction with importi...
متن کاملPARP Inhibitors for Cancer Therapy
Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.
متن کاملAngiogenesis and lung cancer: potential for therapy.
The major cause of death from the most common type of lung cancer, NSCLC, is attributable to metastasis and is responsible for more than 155,000 deaths annually in the United States alone. The prognosis and choice of therapy for patients with lung cancer is currently based on clinical stage and tumor type (1). However, this staging system does not accurately determine an individual patient’s pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomedical Journal of Scientific & Technical Research
سال: 2018
ISSN: 2574-1241
DOI: 10.26717/bjstr.2018.02.000814